IL2 and Miyoshi myopathy: The effect of dexamethasone on lenalidomide activation of NK cells in patients with MM indicates that although the number of circulating NK cells increases after lenalidomide plus dexamethasone treatment, the cytotoxic capacity of NK cells becomes impaired due to dexamethasone-induced suppression of IL-2 production from CD4+ T cells [23].